Clinical study for the effectiveness of Unani drug in Ezema

Therapeutic evaluation of Marham-e-Akbar in Nar-e-farsi -An Observational study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024360

Enrollment

Registered

2020-03-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Marham Akbar: Safeda Kashgari 7 gm Sindur 7 gm Murdarsang 10 gm Phitkiri 7 gm Kath-tha 7 gm Olive oil 10 ml Dose: Quantity sufficient

twice daily for 40 days Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients full-filling Hanifin and Rajkaâ??s criteria 2 Patients with mild to moderate eczema 3 Patients of both gender, 4 Patients in age group of 18 to 65years

Exclusion criteria

Exclusion criteria: 1 Patients who are allergic to any product as well as history or presence any type of malignancy including any skin cancer or suspicious lesions. 2 Any systemic illness 3 Pregnant and lactating mothers.

Design outcomes

Primary

Measure	Time frame
SCORAD -Dermatologic assessments by Severity Scoring of Atopic Dermatitis ( for severity and size of lesions ) Timepoint: Before and After Treatment	—

Secondary

Measure	Time frame
QOL assessments - Dermatologic Life Quality Index (DLQI) Timepoint: Before and After Treatment	—

Countries

India

Contacts

Public ContactMohd Khalid

Luqman Unani Medical College Hospital and Research Center

drqudrathullah@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026